Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Quimatryx S L has 3 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners, meaning each pending matter is being evaluated by a different person. The portfolio's reach extends to 3 distinct art units, indicating that the company's pharmaceutical innovations are being reviewed by three different specialized groups within the patent office.
The busiest examiner identified in the data is WILSON, JERICA KATLYNN, who currently oversees 1 pending case. With 3 pending office actions and 3 distinct examiners, the company faces a diverse set of examination perspectives. This lack of examiner overlap means that insights gained from one application may not directly apply to others, requiring a customized approach for each of the 3 pending matters.
The distribution across 3 distinct art units suggests that the company is pursuing a variety of technical sub-specialties. Practitioners should be prepared to navigate the specific guidelines and precedents of each of these 3 distinct art units. Because no single examiner handles more than 1 pending case, the portfolio's overall progress is not overly dependent on the timeline or temperament of any one individual at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILSON, JERICA KATLYNN | 1 | 60.5% | +39.8% |
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861550 | COMBINATION THERAPIES COMPRISING QTX125 | WILSON, JERICA KATLYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861550 | COMBINATION THERAPIES COMPRISING QTX125 | WILSON, JERICA KATLYNN | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861550 | COMBINATION THERAPIES COMPRISING QTX125 | WILSON, JERICA KATLYNN | 1621 | §103§112 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18858116 | CRYSTALLINE FORMS | SAMSELL, RILLA MARIE | 1624 | §112 | Non-Final OA | — | Pending | Oct 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuimatryx S L has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jerica Katlynn Wilson has the most, with 1 of Quimatryx S L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
